PMID- 13679218
OWN - NLM
STAT- MEDLINE
DCOM- 20040510
LR  - 20190712
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 76
IP  - 1
DP  - 2003 Aug
TI  - Restraint accentuates the effects of 5-HT2 receptor antagonists and a 5-HT1A 
      receptor agonist on lordosis behavior.
PG  - 63-73
AB  - The effect of restraint on lordosis behavior was examined in proestrous and 
      ovariectomized, hormone-primed rats. Restraint durations from 5 to 60 min had no 
      effect on lordosis behavior of proestrous rats. There was also no effect of 5 min 
      restraint on lordosis behavior of ovariectomized rats hormonally primed with 10 
      microg estradiol benzoate and 500 microg progesterone. However, after 
      intraperitoneal treatment with 1.0 mg/kg ketanserin tartrate (ketanserin), 5 min 
      of restraint significantly reduced lordosis behavior of both groups of rats. The 
      5-min restraint combined with 0.50 or 0.75 mg/kg ketanserin reduced lordosis to 
      mount (L/M) ratios of ovariectomized rats, while L/M ratios of proestrous rats 
      were inhibited only by the 1.0 mg/kg dose. Increasing the restraint duration (10 
      or 15 min) reduced the dose of ketanserin necessary to reduce the L/M ratios of 
      proestrous rats. Treatment with the selective serotonin (5-HT)(2C) receptor 
      antagonist, SB206553 (2.5 or 5.0 mg/kg), in combination with 5 min of restraint, 
      also reduced L/M ratios of hormonally primed, ovariectomized rats. The neural 
      sites responsible for ketanserin's additivity with restraint are unknown, but 
      infusion of the drug into the ventromedial nucleus of the hypothalamus (VMN) did 
      not mimic the systemic treatment. However, 5 min of restraint did enhance the 
      effects of VMN infusion with the 5-HT(1A) receptor agonist, 8-OH-DPAT. In 
      contrast, 8-OH-DPAT's systemic potency was not enhanced by restraint. These 
      findings support the hypothesis that a mild stressor increases the 
      lordosis-inhibiting effects of 5-HT(1A) receptor agonists and that 5-HT(2) 
      receptors may protect against such disruption of lordosis behavior.
FAU - Uphouse, Lynda
AU  - Uphouse L
AD  - Department of Biology, Texas Woman's University, PO Box 425799, Denton, TX 
      76204-5799, USA. F-Uphouse@twu.edu
FAU - White, Stacy
AU  - White S
FAU - Harrison, Lance
AU  - Harrison L
FAU - Hiegel, Cindy
AU  - Hiegel C
FAU - Majumdar, Devi
AU  - Majumdar D
FAU - Guptarak, Jutatip
AU  - Guptarak J
FAU - Truitt, William A
AU  - Truitt WA
LA  - eng
GR  - GM55380/GM/NIGMS NIH HHS/United States
GR  - HD28419/HD/NICHD NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Receptors, Serotonin, 5-HT2)
RN  - 0 (Serotonin 5-HT1 Receptor Agonists)
RN  - 0 (Serotonin 5-HT2 Receptor Antagonists)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 112692-38-3 (Receptor, Serotonin, 5-HT1A)
SB  - IM
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Male
MH  - Ovariectomy
MH  - Posture/*physiology
MH  - Proestrus/drug effects/physiology
MH  - Rats
MH  - Rats, Inbred F344
MH  - Receptor, Serotonin, 5-HT1A/physiology
MH  - Receptors, Serotonin, 5-HT2/physiology
MH  - Restraint, Physical
MH  - *Serotonin 5-HT1 Receptor Agonists
MH  - *Serotonin 5-HT2 Receptor Antagonists
MH  - Serotonin Antagonists/pharmacology
MH  - Serotonin Receptor Agonists/pharmacology
MH  - Sexual Behavior, Animal/drug effects/*physiology
EDAT- 2003/09/19 05:00
MHDA- 2004/05/11 05:00
CRDT- 2003/09/19 05:00
PHST- 2003/09/19 05:00 [pubmed]
PHST- 2004/05/11 05:00 [medline]
PHST- 2003/09/19 05:00 [entrez]
AID - S0091305703001941 [pii]
AID - 10.1016/s0091-3057(03)00194-1 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2003 Aug;76(1):63-73. doi: 
      10.1016/s0091-3057(03)00194-1.